Correspondence 0001437749-24-014006 from PULSE BIOSCIENCES, INC. (PLSE)
PULSE BIOSCIENCES, INC.
Date: April 30, 2024 · CIK: 0001625101 · Accession: 0001437749-24-014006
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-278494
Letter
VIA EDGAR Division of Corporation Finance United States Securities and Exchange Commission Amendment No.3 to Registration Statement on Form S-3 Filed April 25, 2024 File No. 333-278494
Re: Pulse Biosciences, Inc.
Dear Sir/Madam:
Pulse Biosciences, Inc. (the “Company”) has filed herewith Amendment No. 4 (the “Fourth Amendment”) to the Company’s Registration Statement on Form S-3, File No. 333-278494, filed with the Commission on April 3, 2024, as amended by each of Amendment No. 1 filed on April 15, 2024, Amendment No. 2 filed on April 23, 2024, and Amendment No. 3 filed on April 25, 2024 (the “Registration Statement”). As requested by the staff of the Division of Corporation Finance of the U.S. Securities and Exchange Commission (the “Staff”) pursuant to a telephonic discussion, the Fourth Amendment specifies the fraction of a Unit that each stockholder of the Company shall be entitled to purchase based on the exercise of each subscription right issued to such stockholder pursuant to the Rights Offering (as defined in the Registration Statement), as well as a recent closing price of the Company’s common stock.
We believe we have been responsive to the Staff’s comments. Please direct any questions concerning this letter to the undersigned at 212.589.4233 or afinerman@bakerlaw.com.
Sincerely,
/s/ Adam Finerman
Show Raw Text
CORRESP 1 filename1.htm plse20240430_corresp.htm April 30, 2024 VIA EDGAR Division of Corporation Finance United States Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Re: Pulse Biosciences, Inc. Amendment No.3 to Registration Statement on Form S-3 Filed April 25, 2024 File No. 333-278494 Dear Sir/Madam: Pulse Biosciences, Inc. (the “Company”) has filed herewith Amendment No. 4 (the “Fourth Amendment”) to the Company’s Registration Statement on Form S-3, File No. 333-278494, filed with the Commission on April 3, 2024, as amended by each of Amendment No. 1 filed on April 15, 2024, Amendment No. 2 filed on April 23, 2024, and Amendment No. 3 filed on April 25, 2024 (the “Registration Statement”). As requested by the staff of the Division of Corporation Finance of the U.S. Securities and Exchange Commission (the “Staff”) pursuant to a telephonic discussion, the Fourth Amendment specifies the fraction of a Unit that each stockholder of the Company shall be entitled to purchase based on the exercise of each subscription right issued to such stockholder pursuant to the Rights Offering (as defined in the Registration Statement), as well as a recent closing price of the Company’s common stock. We believe we have been responsive to the Staff’s comments. Please direct any questions concerning this letter to the undersigned at 212.589.4233 or afinerman@bakerlaw.com. Sincerely, /s/ Adam Finerman Adam Finerman Partner cc: Kevin Danahy, Chief Executive Officer, Pulse Biosciences, Inc.